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ABSTRACT: We developed a three-dimensional fibroblastic
nodule model for fibrogenicity testing of nanomaterials and
investigated the role of fibroblast stemlike cells (FSCs) in the
fibrogenic process. We showed that carbon nanotubes (CNTs)
induced fibroblastic nodule formation in primary human lung
fibroblast cultures resembling the fibroblastic foci in clinical
fibrosis and promoted FSCs that are highly fibrogenic and a
potential driving force of fibrogenesis. This study provides a
predictive 3D model and mechanistic insight on CNT
fibrogenesis.
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Engineered nanomaterials have increasingly been used for awide array of applications in the fields as diverse as
electronics, energy, waste treatment, consumer products, and
medicine. Carbon nanotubes (CNTs) are a major class of
engineered nanomaterials possessing unique mechanical,
electrical, and thermal properties and are being produced on
a massive scale.1,2 The global market for CNTs is estimated to
reach a trillion dollars in the next decade3 with their use
affecting millions of workers and users. Because of their rapid
rise in production and utility, it is important to determine their
unintended consequences, especially on human health and the
environment. CNTs can come into contact with human body
mainly via inhalation and the major target organ of exposure is
the lung. Animal exposure studies have shown that inhaled or
instilled CNTs rapidly entered the alveolar interstitial space to
induce progressive interstitial lung fibrosis without causing
persistent lung injury and inflammation.4−6 Subsequent in vitro
studies showed that CNTs can directly interact with lung
fibroblasts and stimulate their growth and production of
collagen extracellular matrix (ECM) leading to fibrosis.7,8
These effects of CNTs present an enormous health concern
and a great challenge to the assessment of potential health
hazards of CNTs since lung fibrosis is a fatal and incurable
disease with no known effective treatment.
Currently, rodent models are the gold standard for the
assessment of lung fibrosis.9 However, typical animal experi-
ments are laborious and could take months to years to
complete. The use of in vitro models can facilitate the rapid
high-throughput assessment of nanomaterial fibrogenicity and
disease mechanisms.10 An important pathological feature of
lung fibrosis is the accumulation of ECM that is clinically
characterized by fibroblastic foci.11,12 The presence and extent
of such foci is one of the most reliable markers of poor
prognosis in patients with fibrosis.13−15 Xu et al. and Zanotti et
al. recently reported an in vitro model using cell clusters
(nodules) that resemble the foci of renal and muscle
fibrosis.16,17 In this study, we developed a 3D fibroblastic
model of lung fibrosis and investigated the existence of
fibroblast-derived fibrogenic stemlike cells (FSCs) and its role
in fibrogenesis.
Because fibrosis is a progressive disease associated with
aberrant tissue repair and ECM accumulation,1819 identifying
the cells that are capable of repairing the injured tissue and are
the source of ECM production is fundamental to the
understanding of fibrosis mechanisms. Evolving research has
indicated the presence of putative stem cells to be significant in
the development of fibrosis.20,21 Although the presence of FSCs
and its role in fibrogenesis have not been reported, a recent
study has indicated the induction of stem cells at the early onset
of lung fibrosis in a mouse model of bleomycin-induced
fibrosis.21 Because fibroblasts are known to play a key role in
fibrogenesis,8,22 the present study was undertaken to investigate
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whether CNT exposure can induce FSCs and whether these
cells possess fibrogenic activities. FSCs were induced by
exposing primary human lung fibroblasts to CNTs. These
cells were used in this study because they are of human origin
and a better representation of pathological process than
immortalized cell lines that are popularly used but may possess
defective genes affecting fibrosis development. Our results
demonstrated for the first time the induction of FSCs from
normal lung fibroblasts by single-walled (SW) and multiwalled
(MW) CNTs. The FSCs possess a high capacity to generate 3D
fibroblastic nodules, which were further characterized and
assessed as a potential in vitro model for fibrogenicity testing of
nanomaterials.
CNT Characterization and Dose Calculation. SWCNT
were obtained from Carbon Nanotechnology (CNI, Houston,
Texas) and were purified by acid treatment to remove metal
contaminates, while MWCNT were obtained from Mitsui &
Company (New York, NY). Elemental analysis by nitric acid
dissolution and inductive coupled plasma-atomic emission
spectrometry (ICP-AES) showed that purified SWCNT and
MWCNT contained 99% elemental carbon and less than 1% of
contaminants. The metal residues were mostly iron (Fe) at 0.23
and 0.32% by weight in SWCNT and MWCNT, respectively.
The BET surface area, length (L), and width (W) of individual
dry CNT were 400−1040 m2/g, 0.6 ± 0.5 μm (L), and 1 ± 0.2
nm (W) for SWCNT, and 26 m2/g, 8.19 ± 1.7 μm (L), and 81
± 5 nm (W) for MWCNT.23,24 CNTs were dispersed by using
bovine serum albumin (BSA) and were lightly sonicated prior
to culture exposure. The CNT doses used in the in vitro
exposure studies were calculated based on in vivo CNT
exposure data normalized to alveolar surface area in mice. For
example, the doses that induced positive in vivo fibrogenic
Figure 1. Carbon nanotubes induce collagen production of primary human lung fibroblasts. Subconfluent monolayers of cells were treated with
various concentrations (0−0.15 μg/cm2) of SWCNT and MWCNT, or TGF-β (1 ng/mL) for 48 h. (A) Analysis of cell toxicity and proliferation
using MTT assay. (B) Western blot analysis of type I collagen and myofibroblast marker α-SMA. β-actin was used to confirm equal loading of the
samples. (C,D) Quantitative analysis of type I collagen (C) and α-SMA (D). (E) Soluble collagen content by Sircol assay. Data are mean ± SD (n =
4). *p < 0.05 versus vehicle-treated control cells.
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response were 40−80 μg/mouse lung (0.5 mg/kg body
weight).5,6,25 Dividing this dose by the average alveolar surface
area in mice (∼500 cm2)26 indicates the in vitro surface area
dose of 0.08−0.16 μg/cm2. Extrapolation of the experimental
dose to human exposure scenarios in the workplace can be
evaluated using the approach adopted by the National Institute
for Occupational Safety and Health.25,27 Assuming the alveolar
surface area in humans of 100 m2, the human burden is equal to
80−160 mg/Lung. Considering a lung deposition fraction of
30% and a working day inhalation of 10 m3 (a minute
ventilation of 20 L/min), the experimental dose could be
reached within 3−6 months of human inhalation exposure at
400 μg/m3 (high CNT level reported in a research facility)28 or
about 10−20 years at 10 μg/m3 (average CNT level in U.S.
facilities)29 (see Supporting Information Figure S1).
Effects of CNTs on Cell Growth and Collagen
Production of Primary Lung Fibroblasts. A key cellular
mechanism of fibrogenesis is fibroblast activation and
subsequent induction of ECM production and accumula-
tion.30,31 To investigate the effect of CNTs on the fibrogenic
process, primary human lung fibroblasts were treated with
various concentrations (0−0.15 μg/cm2 or 0−0.71 μg/mL) of
SWCNT and MWCNT (see Supporting Information Table S1
for dosimetry) and were evaluated for cell proliferation and
collagen production using MTT and Western blot assays.
Figure 1A shows that SWCNT and MWCNT had no
significant effects on cell proliferation and cytotoxicity at the
indicated concentrations, the results that were confirmed by
CyQuant cell proliferation assay (Invitrogen, Carlsbad, CA)
(data not shown). Figure 1B,C shows that SWCNT, and to a
lesser extent MWCNT, strongly induced type I collagen
production at the dose as low as 0.08 μg/cm2. Transforming
growth factor (TGF)-β, a known fibrosis inducer that was used
in this study as a positive control, similarly induced collagen
production at the concentration of 1 ng/mL. Figure 1B,D
shows an increased expression of myofibroblast marker α-
smooth muscle actin (α-SMA) in SWCNT-, MWCNT- and
TGF-β-treated cells, indicating the transformation of fibroblasts
to myofibroblasts, which is known to be the main source of
collagen production. Analysis of soluble collagen in the cell
culture medium by Sircol assay further showed that both
SWCNT and MWCNT induced collagen secretion from the
treated cells in a dose-dependent manner (Figure 1E).
CNTs Induce Fibroblastic Nodule Formation of
Primary Lung Fibroblasts. An important pathological feature
of lung fibrosis is the presence of fibroblastic foci, which are
aggregates of lung fibroblasts and myofibroblasts and the newly
deposited collagen.11,15 In this study, we developed a 3D
biomimetic model of fibroblastic foci by growing primary
human lung fibroblasts in culture on an adherent substrate
consisting of poly-L-lysine in the presence of TGF-β, a known
inducer of fibrosis. Figure 2A shows the formation of 3D cell
clusters that are referred to as fibroblastic nodules after
treatment of the cells with TGF-β (1 ng/mL) for 16 h.
Interestingly, treatment of the cells with SWCNT or MWCNT
similarly induced the fibroblastic nodules, whereas vehicle-
treated cells showed minimal nodule formation (Figure 2A).
Quantitative analysis for the number of fibroblastic nodules
demonstrated the dose-dependent effect of SWCNT and
MWCNT treatment (Figure 2B). This number correlates well
with the level of collagen produced by the cells as indicated by
the correlation plot depicted in Figure 2C showing the linear
relationship between the two parameters with a goodness of fit
(R2) of 0.8629. To aid visualization of the fibroblastic nodules,
the cells were stained with Hoechst 33342 dye and observed
under a confocal fluorescence microscope. Figure 2D shows the
nodule-forming cell aggregates induced by SWCNT, MWCNT,
and TGF-β but not by control treatment. The orthogonal views
and reconstructed Z-stack image series display 3D morphology
of the fibroblastic nodules (Figure 3 and Supporting
Information Video S1 and S2). These results support the
potential utility of the fibroblastic nodules as an in vitro 3D
model for fibrogenicity testing of nanomaterials.
CNT-Induced Fibroblastic Nodules Contain Abundant
Type I Collagen. Type I collagen is the most abundant ECM
proteins robustly expressed in lung fibrosis.32,33 To further
validate the clinical resemblance of the 3D fibroblastic model,
type I collagen expression was evaluated in SWCNT-,
MWCNT- and TGF-β-induced fibroblastic nodules using
immunofluorescence in comparison with the monolayer of
vehicle-treated control fibroblasts. Figure 4A shows that the
fibroblastic nodules induced by CNTs or TGF-β were enriched
with type I collagen. Together with the cell aggregation data in
Figure 2D, we demonstrate here that the fibroblastic nodules
have important compositional and morphological features of
Figure 2. Carbon nanotubes induce fibroblastic nodule formation of
primary lung fibroblasts. Cells at the density of 3 × 104 cells/24-well
were grown on a poly-L-lysine-coated glass substrate and treated with
various concentrations (0−0.15 μg/cm2) of SWCNT and MWCNT,
or TGF-β (1 ng/mL) for 16 h, which is the optimal time for
fibroblastic formation. (A) Phase contrast micrographs comparing 3D
fibroblastic nodules in control and treated fibroblasts. (B) Quantitative
analysis of fibroblastic nodules. (C) Correlation analysis of the number
of fibroblastic nodules and soluble collagen content. (D) Fluorescence
micrographs of fibroblastic nodules induced by SWCNT, MWCNT,
and TGF-β. Cells were nuclear stained with Hoechst 33342 dye and
observed by confocal fluorescence microscopy. Data are mean ± SD (n
= 3). *p < 0.05 versus vehicle-treated control cells.
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the fibroblastic foci observed in fibrosis patients. The greater
number of fibroblastic nodules in SWCNT as compared to
MWCNT (Figure 2) are consistent with previous in vivo
findings that indicated a greater fibrogenicity of SWCNT than
MWCNT,5,6 thus validating the potential utility of the 3D
fibroblastic nodules as a functional assay for CNT fibrogenicity.
Overall, the advantages of this 3D model over conventional cell
monolayer models include (i) clinical resemblance to human
lung fibrotic lesions; (ii) rapid and quantitative or semi-
quantitative analysis, that is, by colony (nodule) counting as
opposed to the more laborious immunological and biochemical
assays; (iii) fewer cell numbers needed per assay; and (iv)
potential for high-throughput screening, that is, by using
automated colony counter.
CNT-Induced Fibroblastic Nodules Express a High
Level of Putative Stem Cell Markers. Evolving research
indicates the presence of putative stem cells residing in the
lungs to be significant in an early development of lung
fibrosis.21 To investigate the existence of stemlike fibroblasts,
we performed immunofluorescence assays determining the
expression of universal stem cell markers ABCG2 and
ALDH1A134,35 in fibroblastic nodules induced by SWCNT,
MWCNT, and TGF-β. Figure 4B shows that these fibroblastic
nodules expressed a high level of ABCG2 and ALDH1A1 stem
cell markers as compared to vehicle-treated control cells. These
results suggest the presence of stemlike cells in the fibroblastic
nodules and support their role in fibrogenesis. We also
observed CNT deposition in the fibroblastic nodules induced
by SWCNT and MWCNT (Figure 4A and B, arrows) with
minimal presence of CNTs outside the nodules.
CNTs Induce Side Population Phenotype of Primary
Lung Fibroblasts. Adult stem cells are known to efflux
Hoechst dye slowly due to the high expression of ABCG2. Flow
cytometric analysis was used to identify these stem cells with a
Figure 3. Z-stack image series to analyze the 3D structure of
fibroblastic nodules. Cells were grown on a poly-L-lysine-coated glass
substrate, treated with SWCNT or MWCNT (0.15 μg/cm2) and
immunostained for type I collagen (green) and DAPI-stained for
nucleus (blue). (A) X−Y projection of the Z-stack image series from
confocal microscopy with the orthogonal views of X−Z plane
(bottom) and Y−Z plane (right). (B) Three-dimensional reconstruc-
tion was generated based on the results of Z-stack images from panel
A. Calibrated dimensions are width (215.04 μm) × height (215.04
μm) × depth (12, 33.75, and 32.25 μm) in control, SWCNT and
MWCNT, respectively.
Figure 4. Expression of type I collagen and stem cell markers in
carbon nanotube-induced fibroblastic nodules. Cells were grown on a
poly-L-lysine-coated substrate and treated with SWCNT (0.15 μg/
cm2), MWCNT (0.15 μg/cm2), or TGF-β (1 ng/mL) for 16 h. (A)
Fluorescence micrographs of control and fibroblastic nodules induced
by CNTs and TGF-β immunostained for type I collagen (green) and
DAPI-stained for nucleus (blue) by confocal fluorescence microscopy.
(B) Fluorescence micrographs of control and fibroblastic nodules
immunostained for stem cell surface markers ABCG2 (red) and
ALDH1A1 (yellow) by confocal fluorescence microscopy.
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distinct low Hoechst staining pattern referred to as side
population (SP).36,37 An increase in SP population was
reported in the lung of mice with fibrosis, suggesting the
involvement of SP-positive stem cells in lung fibrogenesis.21 To
determine the potential role of stemlike fibroblasts in CNT-
induced fibrogenesis, we first determined the change of SP
subpopulation upon CNT treatment. Primary human lung
fibroblasts were treated with SWCNT or MWCNT at the
concentration of 0.15 μg/cm2 for 48 h, after which they were
incubated with 5 μg/mL of Hoechst 33342 in the presence or
absence of 25 μM fumitremorgin C, an inhibitor of ABC
transporter. Figure 5A shows that both SWCNT and MWCNT
were able to induce the SP subpopulation. The percentage of
SP was approximately 5% in SWCNT-treated fibroblasts and
3% in MWCNT-treated cells versus less than 0.5% in vehicle-
treated control cells (Figure 5B).
Increased Stem Cell Marker and Collagen Expression
in CNT-Derived SP Fibroblasts. To determine the role of
stemlike fibroblasts in CNT-induced fibrogenesis, we isolated
the stemlike cells from SWCNT-treated (0.15 μg/cm2)
fibroblasts based on their SP phenotype using fluorescence-
activated (flow cytometry-based) cell sorting (FACS). Sorted
SP and non-SP fibroblasts were further evaluated for the stem
cell marker ABCG2 and type I collagen expression by
immunofluorescence. Figure 6A,B reveals a substantially higher
expression of ABCG2 in the SP versus non-SP cells, thus
confirming the stemlike phenotype of SP fibroblasts and the
reliability of stem cell isolation by FACS. Importantly, type I
collagen expression was significantly higher in the SP versus
non-SP population. It is widely known that fibroblasts play a
key role in fibrogenesis through its ability to synthesize and
secrete ECM proteins including type I collagen, which
characterizes fibrosis.38,39 Our results thus indicate that the
stemlike fibroblasts are a potential key source of collagen
production and may play a crucial role in fibrogenesis.
CNT-Derived SP Fibroblasts Are Potent Inducer of
Fibroblastic Nodules. To substantiate the functional role of
stem-like fibroblasts in CNT fibrogenesis, the sorted SP and
non-SP cells from CNT-treated fibroblasts were assessed for
their ability to form fibroblastic nodules. Figure 6C shows that
that SP cells had a substantially higher capability to form
fibroblastic nodules than the non-SP fibroblasts. Altogether,
these findings support the role of stemlike fibroblasts in CNT-
induced fibrogenesis.
Figure 5. Carbon nanotubes induce stemlike cells as indicated by side
population phenotype. Fibroblasts were treated with SWCNT (0.15
μg/cm2) or MWCNT (0.15 μg/cm2) for 48 h. (A) Analysis of side
population (SP) in vehicle- and CNT-treated cells in the presence or
absence of fumitremorgin c (FTC) using FACS. SP cells (box) are
determined by their disappearance in the presence of FTC. (B)
Quantitative analysis of SP subpopulation. Data are mean ± SD (n =
4). *p < 0.05 versus vehicle-treated control cells.
Figure 6. An enhanced fibrogenic activity of carbon nanotube-derived
SP fibroblasts. Cells were treated with SWCNT (0.15 μg/cm2) or
MWCNT (0.15 μg/cm2) for 48 h and stained with Hoechst 33342 dye
for side population (SP) analysis. SP fibroblasts were characterized and
isolated by FACS. (A) Fluorescence micrographs of the sorted SP
fibroblasts and parental control non-SP fibroblasts immunostained for
phalloidin (F-actin, green), stem cell marker ABCG2 (red), and type I
collagen (yellow) by confocal fluorescence microscopy. (B)
Quantitative analysis of ABCG2 and type I collagen expression. (C)
Sorted SP and non-SP fibroblasts were grown on a poly-L-lysine-
coated substrate, treated with SWCNT (0.15 μg/cm2), and analyzed
for fibroblastic nodule formation at 16 h post-treatment. Data are
mean ± SD (n = 3). *p < 0.05 versu SP fibroblasts.
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Expression of Stem Cell Markers in Human Lung
Fibrosis Tissues. To provide a supporting evidence for the
clinical relevance of stem cells in lung fibrosis, we performed an
expression analysis of universal stem cell markers ALDH1A1
and ABCG2 in human clinical specimens from fibrotic and
matched normal lung tissues (Origene, Rockville, MD) using
immunohistochemistry and immunofluorescence, respectively.
Figure 7A demonstrates for the first time an upregulation of the
stem cell markers in human lung fibrosis tissues as compared to
matched normal lung tissues. Quantitative analysis of the stem
cell marker expression by Western blotting further showed an
increased expression of ALDH1A1 and ABCG2 in the cell
lysates obtained from lung fibrosis tissues versus matched
normal lung tissues (Figure 7B). These data provide
preliminary supporting evidence for the role of stem cells in
human lung fibrosis. As the high expression of ALDH1A1 and
ABCG2 was similarly observed in the CNT-fibrotic nodules,
these findings strengthen the role of stemlike fibroblasts in
CNT-induced fibrogenesis.
In summary, we have developed a 3D model of CNT lung
fibrogenesis that is fast, robust, and resembles the clinical
fibrotic foci of lung fibrosis. The model employs primary
human lung fibroblasts that form a collagen-rich 3D structure
upon stimulation with CNTs or TGF-β. Using this model, we
unveiled the presence of fibroblast stemlike cells in the
fibroblastic nodules and demonstrated its role in CNT-induced
fibrogenesis. The developed model could potentially be used as
an alternative assay to predict the fibrogenicity of CNTs and
other nanomaterials for their safer design and risk assessment.
In addition, the model could be used to aid mechanistic
investigations of the cellular and molecular events leading to
fibrogenesis.
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